Literature DB >> 11421489

Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update.

C S Elangbam1, R D Tyler, R M Lightfoot.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra- and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of inflammation, and atherosclerosis. Three PPARs, namely alpha, delta, and gamma have been identified with distinct tissue distribution patterns and metabolic functions. PPAR-alpha is predominantly expressed in brown adipose tissue, liver, kidney, duodenum, heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-gamma is highly expressed in brown and white adipose tissues and, to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-delta shows a widespread tissue distribution but its regulation and functions are not yet known. Considerable evidence indicates that PPARs (PPAR-alpha and PPAR-gamma) have beneficial effects in inflammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, fibrinolysis, and modulation of monocyte-derived macrophages. In this review, the general and specific roles of the PPAR isotypes and their implications in the control of vascular inflammation and atherosclerosis are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11421489     DOI: 10.1080/019262301317052495

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  7 in total

1.  The involvement of the CD40-CD40L pathway in activated platelet-induced changes in HUVEC COX-2 and PPARα expression.

Authors:  Yan-qing Wu; Xiao-shu Chen; Jun-bing Chai
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.

Authors:  David J van Westerloo; Sandrine Florquin; Anita M de Boer; Joost Daalhuisen; Alex F de Vos; Marco J Bruno; Tom van der Poll
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

3.  Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells.

Authors:  Chan Woo Cheon; Dae Hwan Kim; Dong Heon Kim; Yong Hoon Cho; Jae Hun Kim
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

4.  Activation of peroxisome proliferator-activated receptors alpha and gamma1 inhibits human smooth muscle cell proliferation.

Authors:  Peter Zahradka; Natalia Yurkova; Brenda Litchie; Michael C Moon; Dario F Del Rizzo; Carla G Taylor
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

Review 5.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Dihydrocapsaicin Attenuates Plaque Formation through a PPARγ/LXRα Pathway in apoE(-/-) Mice Fed a High-Fat/High-Cholesterol Diet.

Authors:  Yan-Wei Hu; Xin Ma; Jin-Lan Huang; Xin-Ru Mao; Jun-Yao Yang; Jia-Yi Zhao; Shu-Fen Li; Yu-Rong Qiu; Jia Yang; Lei Zheng; Qian Wang
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

7.  PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities.

Authors:  Mylène Perreault; David V Erbe; James F Tobin
Journal:  PPAR Res       Date:  2008-10-29       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.